Apnimed, Inc. (APMD)
Apnimed, Inc. operates as a clinical pharmaceutical company that develops and manufactures novel oral therapies that address the neurobiology of sleep-related breathing diseases in global markets. Its products include AD109, an oral therapy designed to treat obstructive sleep apnea (OSA) by targeting the underlying neuromuscular dysfunction. The company was incorporated in 2017 and is based in Cambridge, Massachusetts.
Sector: Pharmaceutical Preparations
Industry: Biotechnology
Apnimed, Inc.
No financial data available.
No debt & equity data available.
No splits on record
Nothing in APMD's public trading history: no forward or reverse split has affected the share count.
No balance sheet details available.
No income statement data available.
No balance sheet data available.
No cash flow data available.